Human IL-12A (also known as p35) is a gene that encodes the alpha-subunit (p35) of the heterodimeric cytokine Interleukin-12 (IL-12). Synthesized as a 219-amino-acid polypeptide with an immunoglobulin-like domain, the mature p35 subunit covalently binds via disulfide bonds to the p40 subunit (encoded by IL12B) to assemble the biologically active IL-12 p70 complex. Alternatively, IL-12A can pair with EBI3 to form IL-35, an immunosuppressive cytokine.
As part of the IL-12 complex, IL-12A is primarily secreted by professional antigen-presenting cells (APCs) like dendritic cells and macrophages. It bridges innate and adaptive immunity by binding to the IL-12Rβ1/β2 receptor complex. This engagement activates the JAK2/TYK2 pathway, leading to the phosphorylation of STAT4. This signaling cascade induces interferon-gamma (IFN-γ) production, drives the differentiation of naive T cells into T helper 1 (Th1) cells, and enhances the cytotoxic activity of natural killer (NK) and CD8+ T cells. Conversely, when serving as a subunit of IL-35, it plays a vital role in maintaining immune homeostasis and suppressing inflammatory responses.
Due to its powerful ability to stimulate a Th1-mediated immune response and promote anti-angiogenic pathways, IL-12 holds significant therapeutic potential. Because systemic administration of recombinant IL-12 causes severe toxicities, modern applications utilize local gene therapies, tumor-targeting immunocytokines, and IL-12-conditioned T-cell infusions to safely eliminate tumors.
Because overproduction of IL-12 drives tissue damaging chronic inflammation, blocking this pathway is highly effective. Monoclonal antibodies targeting the IL-12 signaling axis are successfully utilized to treat severe autoimmune conditions like psoriasis, inflammatory bowel disease (IBD), and multiple sclerosis.




Reviews
There are no reviews yet.